文献速递临床试验与 GCP流行病学与生物统计

难治性院外心脏骤停中停搏期间转运、体外心肺复苏及即刻有创评估与治疗对功能性神经结局的影响:一项随机临床试验

Effect of Intra-arrest Transport, Extracorporeal Cardiopulmonary Resuscitation, and Immediate Invasive Assessment and Treatment on Functional Neurologic Outcome in Refractory Out-of-Hospital Cardiac Arrest: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2022-01-01

在捷克布拉格单中心纳入256例难治性院外心脏骤停成人,比较停搏期间转运联合体外心肺复苏及即刻有创评估治疗策略与标准复苏。有创策略组180天良好神经结局生存率31.5% vs 标准策略组22.0%,差异未达统计学显著(P=.09)。试验因预设无效性标准提前终止,原文认为可能把握度不足。

要点

  • 有创策略组180天良好神经结局生存31.5%,标准策略组22.0%,差异9.5%(95%CI -1.3%至20.1%),P=.09。
  • 30天神经恢复有创策略组30.6% vs 标准策略组18.2%,OR 1.99(95%CI 1.11至3.57),P=.02。
  • 有创策略组出血发生率31%,标准策略组15%。

核心结论

  • 在难治性院外心脏骤停患者中,停搏期间转运联合体外心肺复苏及有创评估治疗的策略组合,与标准复苏相比未显著改善180天良好神经结局生存。
  • 原文指出该试验可能把握度不足,无法检出有临床意义的差异。

研究设计与样本

  • 单中心随机临床试验,地点为捷克共和国布拉格,纳入见证下推测心源性且未恢复自主循环的院外心脏骤停成人。
  • 计划样本量285例,实际入组256例,入组时间为2013年3月至2020年10月,随访至死亡或第180天,末例随访于2021年3月30日结束。
  • 有创策略组124例,标准策略组132例;因预设无效性标准达到,经数据与安全监查委员会建议终止试验。

主要发现

  • 256例患者中位年龄58岁,女性44例(17%),256例(100%)完成试验。
  • 180天良好神经结局生存:有创策略组39例(31.5%)vs 标准策略组29例(22.0%),OR 1.63(95%CI 0.93至2.85),差异9.5%(95%CI -1.3%至20.1%),P=.09。
  • 30天神经恢复:有创策略组38例(30.6%)vs 标准策略组24例(18.2%),OR 1.99(95%CI 1.11至3.57),差异12.4%(95%CI 1.9%至22.7%),P=.02。
  • 30天心脏恢复:有创策略组54例(43.5%)vs 标准策略组45例(34.1%),OR 1.49(95%CI 0.91至2.47),差异9.4%(95%CI -2.5%至21%),P=.12。
  • 出血发生率有创策略组31% vs 标准策略组15%。

关键数值与推荐

  • 主要结局为随机化后180天良好神经结局生存,定义为脑功能分级(CPC)1-2。
  • 次要结局包括30天神经恢复(30天内任一时点CPC 1-2)和30天心脏恢复(至少24小时无需药物或机械心脏支持)。

临床怎么用

  • 原文结论未据此给出临床推荐。

局限性

  • 试验因预设无效性标准达到而提前终止,原文指出该试验可能把握度不足,无法检出有临床意义的差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Out-of-hospital cardiac arrest (OHCA) has poor outcome. Whether intra-arrest transport, extracorporeal cardiopulmonary resuscitation (ECPR), and immediate invasive assessment and treatment (invasive strategy) is beneficial in this setting remains uncertain. OBJECTIVE: To determine whether an early invasive approach in adults with refractory OHCA improves neurologically favorable survival. DESIGN, SETTING, AND PARTICIPANTS: Single-center, randomized clinical trial in Prague, Czech Republic, of adults with a witnessed OHCA of presumed cardiac origin without return of spontaneous circulation. A total of 256 participants, of a planned sample size of 285, were enrolled between March 2013 and October 2020. Patients were observed until death or day 180 (last patient follow-up ended on March 30, 2021). INTERVENTIONS: In the invasive strategy group (n = 124), mechanical compression was initiated, followed by intra-arrest transport to a cardiac center for ECPR and immediate invasive assessment and treatment. Regular advanced cardiac life support was continued on-site in the standard strategy group (n = 132). MAIN OUTCOMES AND MEASURES: The primary outcome was survival with a good neurologic outcome (defined as Cerebral Performance Category [CPC] 1-2) at 180 days after randomization. Secondary outcomes included neurologic recovery at 30 days (defined as CPC 1-2 at any time within the first 30 days) and cardiac recovery at 30 days (defined as no need for pharmacological or mechanical cardiac support for at least 24 hours). RESULTS: The trial was stopped at the recommendation of the data and safety monitoring board when prespecified criteria for futility were met. Among 256 patients (median age, 58 years; 44 [17%] women), 256 (100%) completed the trial. In the main analysis, 39 patients (31.5%) in the invasive strategy group and 29 (22.0%) in the standard strategy group survived to 180 days with good neurologic outcome (odds ratio [OR], 1.63 [95% CI, 0.93 to 2.85]; difference, 9.5% [95% CI, -1.3% to 20.1%]; P = .09). At 30 days, neurologic recovery had occurred in 38 patients (30.6%) in the invasive strategy group and in 24 (18.2%) in the standard strategy group (OR, 1.99 [95% CI, 1.11 to 3.57]; difference, 12.4% [95% CI, 1.9% to 22.7%]; P = .02), and cardiac recovery had occurred in 54 (43.5%) and 45 (34.1%) patients, respectively (OR, 1.49 [95% CI, 0.91 to 2.47]; difference, 9.4% [95% CI, -2.5% to 21%]; P = .12). Bleeding occurred more frequently in the invasive strategy vs standard strategy group (31% vs 15%, respectively). CONCLUSIONS AND RELEVANCE: Among patients with refractory out-of-hospital cardiac arrest, the bundle of early intra-arrest transport, ECPR, and invasive assessment and treatment did not significantly improve survival with neurologically favorable outcome at 180 days compared with standard resuscitation. However, the trial was possibly underpowered to detect a clinically relevant difference. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01511666.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Belohlavek J, Smalcova J, Rob D, et al. Effect of Intra-arrest Transport, Extracorporeal Cardiopulmonary Resuscitation, and Immediate Invasive Assessment and Treatment on Functional Neurologic Outcome in Refractory Out-of-Hospital Cardiac Arrest: A Randomized Clinical Trial. JAMA. 2022. PMID: 35191923. doi:10.1001/jama.2022.1025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。